Abstract
Renewed commitment to cardiovascular drug development is needed to combat what is likely to be the leading cause of death for the next two decades. How might this be achieved?
This is a preview of subscription content, log in via an institution to check access.
References
Garber, A. M. An uncertain future for cardiovascular drug development? N. Engl. J. Med. 360, 12 (2009).
World Health Organization. Cardiovascular diseases (CVDs), [online] (2009)
Yang, W. et al. Prevalence of diabetes among men and women in China. N. Engl. J. Med. 362, 1090–1101 (2010).
FDA approves updated warfarin (Coumadin) prescribing information. [online], (2007).
Teslovich, T. M. et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466, 707–713 (2010).
Calhoun, D. A. et al. Resistant hypertension: diagnosis, evaluation, treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 51, 1403–1419 (2008).
Amar, L. et al. Aldosterone synthase inhibition with LCI699. A proof-of-concept study in patients with primary aldosteronism. Hypertension 13 Sep 2010 (doi: 10.1161/HYPERTENSIONAHA.110.157271).
Connolly, S. J. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139–1151 (2009).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
A.P. is employed by Merck and Co., Inc. Whitehouse Station, New Jersey, USA.
Supplementary information
Supplementary information Figure S1
50 years of advances in cardiovascular disease therapies. (PDF 260 kb)
Supplementary information Figure S2
Alliances by therapeutic category. (PDF 191 kb)
Rights and permissions
About this article
Cite this article
Plump, A. Accelerating the pulse of cardiovascular R&D. Nat Rev Drug Discov 9, 823–824 (2010). https://doi.org/10.1038/nrd3315
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3315
- Springer Nature Limited
This article is cited by
-
Purinergic receptors in the carotid body as a new drug target for controlling hypertension
Nature Medicine (2016)
-
Insights from systems pharmacology into cardiovascular drug discovery and therapy
BMC Systems Biology (2014)
-
The carotid body as a putative therapeutic target for the treatment of neurogenic hypertension
Nature Communications (2013)
-
The sympathetic nervous system and blood pressure in humans: implications for hypertension
Journal of Human Hypertension (2012)
-
Neurogenic Hypertension and Elevated Vertebrobasilar Arterial Resistance: Is There a Causative Link?
Current Hypertension Reports (2012)